Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib

Show full item record



Permalink

http://hdl.handle.net/10138/313220

Citation

Crona , D J , Skol , A D , Leppänen , V-M , Glubb , D M , Etheridge , A S , Hilliard , E , Pena , C E , Peterson , Y K , Klauber-DeMore , N , Alitalo , K K & Innocenti , F 2019 , ' Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib ' , Cancer Research , vol. 79 , no. 1 , pp. 231-241 . https://doi.org/10.1158/0008-5472.CAN-18-1089

Title: Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
Author: Crona, Daniel J.; Skol, Andrew D.; Leppänen, Veli-Matti; Glubb, Dylan M.; Etheridge, Amy S.; Hilliard, Eleanor; Pena, Carol E.; Peterson, Yuri K.; Klauber-DeMore, Nancy; Alitalo, Kari K.; Innocenti, Federico
Contributor: University of Helsinki, Kari Alitalo / Principal Investigator
University of Helsinki, HUSLAB
Date: 2019-01-01
Language: eng
Number of pages: 11
Belongs to series: Cancer Research
ISSN: 0008-5472
URI: http://hdl.handle.net/10138/313220
Abstract: Molecular markers of sorafenib efficacy in patients with metastatic renal cell carcinoma (mRCC) are not available. The purpose of this study was to discover genetic markers of survival in patients with mRCC treated with sorafenib. Germline variants from 56 genes were genotyped in 295 patients with mRCC. Variant-overall survival (OS) associations were tested in multivariate regression models. Mechanistic studies were conducted to validate clinical associations. VEGFA rs1885657, ITGAV rs3816375, and WWOX rs8047917 (sorafenib arm), and FLT4 rs307826 and VEGFA rs3024987 (sorafenib and placebo arms combined) were associated with shorter OS. FLT4 rs307826 increased VEGFR-3 phosphorylation, membrane trafficking, and receptor activation. VEGFA rs1885657 and rs58159269 increased transcriptional activity of the constructs containing these variants in endothelial and RCC cell lines, and VEGFA rs58159269 increased endothelial cell proliferation and tube formation. FLT4 rs307826 and VEGFA rs58159269 led to reduced sorafenib cytotoxicity. Genetic variation in VEGFA and FLT4 could affect survival in sorafenib-treated patients with mRCC. These markers should be examined in additional malignancies treated with sorafenib and in other angiogenesis inhibitors used in mRCC. Significance: Clinical and mechanistic data identify germline genetic variants in VEGFA and FLT4 as markers of survival in patients with metastatic renal cell carcinoma.
Subject: FACTOR-TARGETED THERAPY
MULTIKINASE INHIBITOR
LIGAND-BINDING
GROWTH
CANCER
ANGIOGENESIS
ASSOCIATION
ACTIVATION
MECHANISMS
3111 Biomedicine
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Genetic_variants_of_VEGFA_and_FLT4.pdf 880.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record